AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Written by Petra Hegmann on 22nd December 2021. Posted in Client News.

• Previous
• Next